to-BBB and Lundbeck to join forces on brain delivery of antibodies for CNS diseases
“We are very pleased to collaborate with Lundbeck,” says Pieter Gaillard, CSO of to-BBB. “to-BBB’s brain delivery technology combined with Lundbeck’s strong knowledge in the area of CNS disorders, should result in further progress to improve the lives of patients with devastating brain diseases.”
Lundbeck is an international pharmaceutical company engaged in research to find new drugs for treatment of CNS disorders, including depression, schizophrenia, Alzheimer’s disease and Parkinson’s disease. The collaboration with to-BBB could provide Lundbeck with an opportunity to improve the brain delivery of therapeutic antibodies addressing CNS diseases.
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous